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Abstract: The aim of the study was to
establish apolipoprotein E genotype in the
patients with coronary heart disease (CHD)
who are inhabitants of the north-east of
Turkey.
The study involved 106 patients (70 male, 36
female; ages ranging from 37 to 69 years)
who are local people and were
angiocardiographically diagnosed for CHD.
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The risk factors such as smoking, alcohol and
obesity were determined and serum
triglyceride, total cholesterol, LDL and HDL
were measured in the subjects. Each patient
sample was apolipoprotein E genotyped,
which was achieved by PCR amplification of
the 227 bp region followed by Cfo I digestion
to release specific band patterns.
Subjects with CHD had more hypertension
than the control (20.8% vs 7.7%, p: 0.038,
z:-2.074), whereas risk factors such as
smoking, obesity, alcohol and sedentary lifestyle were not more frequent in patients with
CHD than in healthy controls.
Distribution of apolipoprotein E genotypes
among the patients was 5.7% E4/E4 (n=6),
22.6% E4/E3 (n=24), 62.3% E3/E3 (n=66),
7.5% E3/E2 (n:8), 0.94% E2/E2 (n:1) and
0.94% E4/E2 (n:1). The control group
exhibited 1.9% E4/E4 (n:1), 9.6% E4/E3
(n:5), 61.5% E3/E3 (n:32), 19.2% E3/E2
(n:10), 3.8% E2/E2 (n:2) and 3.8% E4/E2
(n:2). In our study, the most common
apolipoprotein E genotype obtained was

E3/E3, either in patients with CHD or in the
healthy control group. Therefore, the
difference between the groups was not
significant (62.3% and 61.5%, p: 0.92
respectively). The genotype E3/E3 of
apolipoprotein E in patients with CHD was,
however, significantly high, as compared to
healthy controls (22.6% vs 9.6%; p: 0.0476,
z:-1.98). The frequency of the E3/E2
genotype was significantly higher in the
control group than in patients with CHD
(19.2% vs 7.5%; p: 0.03, z:-2.16).
Mean total cholesterol levels in CHD patients
were 175.4±29.4 mg/dl, while they were
164.4±28.6 mg/dl in the control group (t:
2.26, p: 0.026). Mean LDL-C levels were
107.9±24.6 mg/dl in patients and 99.5±23.6
mg/dl in the control group (t: 2.04, p:
0.043). There were no significant differences
between the two groups regarding
triglyceride and HDL-Cholesterol. On the
other hand, the levels of total cholesterol and
LDL-C in patients with CHD were significantly
different according to apolipoprotein E
genotypes.
In conclusion, according to our study, the
E4/E3 genotype was the most common
genotype in patient with CHD. This finding, at
least in part, could explain one of the
important risk factors for coronary heart
disease in subjects in eastern Turkey.
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Introduction

coronary heart disease (1,2).

Lipoproteins are an important determinant of
atherosclerotic vascular disease in man. The serum
concentration and metabolism of lipoproteins are largely
modulated by apolipoproteins and it has therefore been
hypothesized that genetic variations in apolipoproteins
are associated with variations in the susceptibility to

There is a significant effect of apolipopotein E on
plasma cholesterol levels and it is responsible by itself for
10% variations in cholesterol levels among individuals
within the population (3). Polymorphism of
apolipoprotein E has recently received increasing
attention.
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Three common alleles, E2, E3 and E4, determine the
six apolipoprotein E genotypes E2/E2, E2/E3, E2/E4,
E3/E3, E4/E3 and E4/E4 (4). High cholesterol and LDL
metabolisms are associated with apolipoprotein E
polymorphism such that subjects with the genotypes
E4/E3 have higher concentrations. Patients with CHD
have an increased risk of all manifestations of
atherosclerotic vascular disease (5).
The aim of the study was to establish apolipoprotein
E genotype in the patients with CHD who are inhabitants
of the north-east of Turkey and to find out the relation
between apolipoprotein E genotype and the disease.

Materials and Methods
In the study, we selected 106 patients with CHD who
were admitted to the cardiology department of University
hospital, (aged 37-69; 36 female, 70 male) and 52
healthy controls (aged 40-65; 20 female, 32 male) who
had asymptomatic CHD and normal electrocardiography
from the eastern part of Turkey. The controls were
completely representative of the non-CHD population of
the study area. None of the control or CHD patients were
receiving hypolipidemic drugs and none had a significant
impairment in renal function as assessed by serum
creatinine concentration. There was no diabetes mellitus
or other disease which might affect the lipid profiles.
Thirty patients had a history of myocardial infarction
according to their medical records, and the remaining
subjects were assessed as having unstable angina pectoris
(UAP) according to WHO criteria (6). According to
coronary angiography reports, 32 patients had one
coronary artery disease and 58 patients exhibited two or
more coronary artery lesions.
Serum cholesterol, LDL, HDL and triglyceride
concentration were determined from fresh serum
samples drawn after a 12-hour overnight fast.
The apolipoprotein E genotype was determined by
PCR amplification of the 227 bp region followed by CfoI
digestion to release the specific band pattern.
Genomic DNA was isolated from blood (7).
Amplification of the apolipoprotein E target sequence was
performed
by
using
the
5-primer
TCCAAGGAGCTGCAGGCGGCGCA
and
3-primer
ACAGAATTCGCCCCGGCCTGGTACACTGCCA. This primer
pair amplifies a 227 bp region of DNA that spans both
230

apolipoprotein E polymorphic sites. About 15 ml of PCR
products were run on 3% agarose gel.
The major band was seen to correspond to a
molecular weight of approximately 227 bp. 15 µl of
amplification products was subjected to restriction by
CfoI. The digested products were electrophoresed,
stained with ethidium bromide and viewed and
photographed under UV light.
SSPS 6.1 software was used for statistical analysis.

Results
Table 1 lists the characteristics of the study groups.
Subjects with CHD had more hypertension than the
control subjects, whereas risk factors such as smoking,
obesity and alcohol were not frequent in subjects with
CHD compared to the healthy controls.

Table 1.

Characteristics of control subjects and subjects with CHD.

No of Subjects
Sex (F/M)
Mean (SD) Age (years)
No. (%) of Smokers
No. (%) of Obesity (a)
No. (%) of Alcohol users
No. (%) Hypertension (b)
No (%) Sedentary life style

Controls

CHD

p Values

52
29/23
47.9±6.4
24 (46.2)
16 (30.8)
4 (7.7)
4 (7.7)
20 (38.4)

106
54/62
49.8±7.4
50 (47.2)
26 (24.5)
7 (6.6)
22 (20.8)
48 (42.3)

P
p
p
p
p
P
P

(NS)*
(NS)**
(NS)*
(NS)*
(NS)*
0.038
(NS)*

Statistical analysis within the table were made with *Chi-square test and
**Unpaired Student’s t test
a. Subjects who have Body mass index > 30 kg/m2 were considered
as obese (8).
b. Subjects who have blood pressure > 140/90 mmHg were
considered as hyperactive (9).

Table 2 shows the distribution of apolipoprotein E
genotypes among the patients and healthy controls. The
most common apolipoprotein E genotype both in CHD
patients and in the control group was E3/E3 and the
difference was not significant (62.3% and 61.5%, p:
0.92 respectively). The frequency of the E4/E3 genotype
was much higher in subjects with CHD than in the control
group and the difference was statistically significant
(22.6% and 9.6%; p: 0.0476, z:-1.98 respectively). The
E3/E2 genotype appeared to be more in control than in
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Table 2.

Apolipoprotein E Genotypes in Control and CHD.

GENOTYPES

E4/E4
E4/E3
E3/E3
E3/E2
E2/E2
E4/E2

CONTROL (n:52)
No (%)

CHD (n:106)
No (%)

1 (1.9)
5 (9.6)
32(61.5)
10 (19.2)
2 (3.8)
2 (3.8)

6 (5.7)
24 (22.6)*
66 (62.3)
8 (7.5)**
1 (0.94)
1 (0.94

*p:0.0476 compared to control group
**p:0.03 compared to CHD group

CHD patients (19.2% and 7.5%; p: 0.03, z:-2.16
respectively).
Table 3 represents the mean serum lipid
concentration in the two groups. The mean total
cholesterol and LDL-C levels were significantly higher in
patients with CHD than in the control group (for total
cholesterol t: 2.26, p: 0.026; for LDL-C t: 2.04, p:
Table 3.

0.043). There was no significant correlation between the
two groups regarding triglyceride and HDL-C. The
relation between apolipoprotein E genotypes and serum
lipid levels in both groups is indicated in Table 4.
The total cholesterol values determined among
patients with CHD were significantly different in the
apolipoprotein E genotypes obtained within the group
(chi square 21.26 and p: 0.0007). Similary, LDL-C levels
were also different among apolipoprotein E genotypes
obtained in the patient group (chi square 16.6 and p:
0.0053).
Discussion
The most common isoforms of apolipoprotein E (E2,
E3, E4) affect the level of lipids and their profiles
(11,12). Likewise, it has been shown that apolipoprotein
E2 is associated with lower plasma cholesterol and
apolipoprotein E4 has a contrary effect (11-14). On the
other hand, some studies have shown a significant

Mean Levels of Plasma Lipids According to Apolipoprotein E Genotyping in Patients with CHD.

CHD (n=90)

E2/E2

E3/E2

E3/E3 (n=20)

E4/E3 (n=32)

E4/E4 (n=38)

Total- C mg/dl
> 200 n (%)

-

-

126.5 ± 37.2
0 (0)

181.3 ± 41.7
10 (31)

180.2 ± 61.4
14 (37)

LDL-C mg/dl
> 130 n (%)

-

-

59.1 ± 39.9
0 (0)

125.8 ± 39.6
11 (34)

118.5 ± 53.7
13 (34)

HDL-C mg/dl< 35 n (%)

-

-

30.3 ± 6.6
14 (70)

25.4 ± 6.4
23 (72)

28.5 ± 5.7
29 (76)

TG mg/dl
> 200 n (%)

-

-

150.5 ± 65.1
8 (40)

159.3 ± 50.5
12 (38)

160.1 ± 62.5
16 (42)

Table 4.

Mean Levels of Plasma Lipids According to Apolipoprotein E Genotyping in Patients with Healthy Controls.

Controls (n=52)

E2/E2 (n=6)

E3/E2 (n=10)

E3/E3 (n=18)

E4/E3 (n=9)

E4/E4 (n=9)

Total- C mg/dl
> 200 n (%)

143.1 ± 46.8
0 (0)

152.2 ± 45.7
0 (0)

140.9 ± 56.1
0 (0)

175.3 ± 58.2
3 (33)

172.9 ± 57.5
3 (33)

LDL-C mg/dl
> 130 n (%)

82.0 ± 51.6
0 (0)

95.7 ± 48.7
1 (10)

79.9 ± 46.9
0 (0)

120.4 ± 57.8
3 (33)

124.8 ± 37.7
3 (33)

HDL-C mg/dl
< 35 n (%)

30.8 ± 6.6
2 (33)

30.0 ± 7.25
4 (40)

28.3 ± 7.1
12 (67)

26.6 ± 9.6
6 (67)

26.8 ± 7.0
7 (78)

TG mg/dl
> 200 n (%)

150.0 ± 70.0
2 (33)

148.0 ± 72.9
3 (30)

155.9 ± 77.9
3 (33)

170.2 ± 45.6
3 (33)

184.1 ± 43.3
3 (33)

Plasma concentrations (mean ± SD) of lipids (mg/dl) in CVD patients as a function of apolipoprotein-E polymorphism. Cut-off values were accepted
for total-C >200 mg/dl, LDL-C >130 mg/dl, HDL-C< 35 mg/dl and TG > 200 mg/dl (10). Statistical evaluations were performed according to these
values.
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increase in the frequency of the E4 allele in survivors of
myocardial infarction or in patients with angiographically
verified coronary heart disease (15). Furthermore, the
allele E4 has been observed to increase the risk of
myocardial infarction at an early age (16).
The apolipoprotein alleles frequency in Turkey is
74.2% E3/E3, 12.9% E4/E3, 10.6% E3/E2, 1.1%
E4/E4, 0.8% E4/E2 and 0.4% E2/E2 according to the
Turkish Heart Study (17). In our study, although the
E3/E3 genotype was the most common, there was no
significant correlation between the CHD group and the
control group. The genotype of E4/E3 in patients with
CHD was more common than in the to healthy controls
(p: 0.047). Our results (Table 2) were consistent with
other group work regarding the E4 allele and coronary
artery disease (5, 15-20). On the other hand, besides the
frequency of E3/E2 genotype being much lower in CHD
group than in the control group (Table 2; 7.5% and
19.2%, p: 0.03 respectively), serum total cholesterol and
LDL-C levels appeared to be much higher than in the
control group (Table 4). It might, however, be difficult to
interpret for regional distribution of the apolipoprotein E
genotype and to use it as a risk factor for CHD, since the
number of subjects studied was not high enough.
Why should people with the E4 allele be particularly
susceptible to coronary heart disease? It seems that the
risk for coronary heart disease could be related to the
impact of the apolipoprotein E genotypes or serum lipid
and lipoprotein concentration. Apolipoprotein E
participates in the conversion of VLDL remnants to LDL,
and this metabolic pathway is particularly effective in
subjects with the E4 allele, which might result in a higher
rate of production of LDL in these subjects (21).
Furthermore, the HDL subfraction containing
apolipoprotein E is considered to play an important part
in the reverse cholesterol transport (22).
High LDL concentrations in people with the E4 allele
seem to be related to the particularly effective absorption

of the cholesterol in these subjects, which may be one
explanation for the differences in LDL concentrations
among people with the various apolipoprotein E
genotypes (23).
In our study, high levels of total cholesterol (> 200
mg/dl) and LDL-C (> 130 mg/dl) which are accepted risk
factors for CHD, were more frequent in patients than in
the healthy controls (Table 3).
It is known that there is no direct relation between
apolipoprotein E alleles and HDL-C. It has, however, been
reported that HDL-C levels could be lowered in cases of
overrepresentation of apolipoprotein E (17). In our
study, the level of HDL-C was under the expected values
(> 35 mg/dl) in both the CHD and control groups (Table
3).
Although an association between an increase in serum
TG levels and CHD incidence is disputed, it has been
proposed that there is a relation between increased
serum TG level and CHD risk (1,6,11). There was also no
considerable difference between the CHD and control
groups in terms of serum triglyceride concentration.
Subjects with CHD had more hypertension and were
less physically active (in other words had a sedentary lifestyle) than the control subjects, whereas no differences in
other cardiovascular risk factors (smoking, alcohol
consumption and obesity) were found between the
groups of CHD and healthy controls. This finding may
support the idea that the susceptibility to coronary heart
disease cannot be explained by these classic cardiovascular
risk factors alone.
According to our study results, the more frequent
appearance of the apolipoprotein E4/E3 genotype in
patients with CHD, using also that genotype as a risk
factor for CHD in the region and association of
apolipoprotein E distribution with total LDL-C levels that
is a risk factor for CHD patients, may be useful for
understanding the regional profile of the disease related
to apolipoprotein E genotypes and lipid profiles.

References
1.

232

Davignon J, Gregg RE, Sing CF.
Apolipoprotein E polymorphism and
atherosclerosis. Arteriosclerosis. 8: 121, 1988.

2.

Miller D.B, Hegele RA, Wolfe BM, Huff
MW.
Identification
molecular
characterization and cellular studies of
an apolipoprotein E mutant (E I) in three
unrelated families with hyperlipidemia.
JCEM. 80 (3): 807-13, 1995.

3.

Innerarity TL., Mahley RW, Weisgarber
KH, Bersot TP, Krauss RM, Vega GL,
Grundy SM, Friedl W, Davignon J, and
McCarthy BJ. Familial defective
apolipoprotein B-100: a mutation of
apolipoprotein
B
that
causes
hypercholesterolemia. J Lipid Res. 31:
1337-1349, 1990.

‹. P‹R‹M, F. POLAT, E. AKARSU, Y.N. fiAH‹N, E. BOZKURT

4.

Sing CF., Davignon J. Role of Apo E
polymorphism in determining normal
plasma lipid and lipoprotein variation.
Am J. Hum Genet. 37: 268-85, 1985.

5.

Laakso M., Kesaniemi A., Kervinen K.
Relation of Coronary Heart Disease and
apolipoprotein E phenotype in patients
with noninsulin dependent diabetes.
BMJ. 303: 1159-62, 1991.

6.

7.

8.

9.

10.

11.

World Health Organization. Proposal for
the multinational monitoring of trends
and determinants in cardiovascular
disease and protocol (MONICA project)
Geneva: WHO (WHO/MNC – 82-1,Rev
1).
Ghebremedhin E, Brook H., Brook E.
Improved method facilitates reliable Apo
E genotyping of genomic DNA extracted
from formaldehyde-fixed pathology
specimens. J of Neuroscience Methods.
79 (2): 229-31, 1998.
Kuczmarski RJ., Flegal KM., Campbell
SM., Johnson CL. Increasing prevalence
of overweight amongst US adults. The
National
Health
and
Nutrition
Examination Surveys, 1960 to 1991.
JAMA. 272: 205-211, 1994.
Sixth Report of the Joint National
Committee on prevention, detection,
evaluation, and treatment of high blood
pressure (JNC VI). Arch. Intern Med.
157: 2413-2446, 1997.
Expert Panel on Detection, Evaluation,
and Treatment of High Blood
Cholesterol education Program (NCEP)
Expert Panel on Detection, Evaluation,
and Treatment of High Blood
Cholesterol in Adults (adult Treatment
Panel II). JAMA. 269: 3015-3023,
1993.
Mahley RW. Apolipoprotein E:
cholesterol transport protein with
expanding role in cell biology. Science.
240: 622-630, 1988.

12.

Mahley RW., Rall, Jr. SC. Tye III
hyperlipoproteinemia
(dysbetalipoproteinemia): the role of apolipoprotein
E in normal and abnormal lipoprotein
metabolism. In The Metabolic and
Molecular Bases of Inherited Disease.
th
7 edition. Scriver CR., Beaudet AL., Sly
WS., Valle D., eds. McGraw-Hill, New
York. 1953-1980, 1995.

13.

Utermann G., Pruin N., Steinmetz A.
Polymorphism of apolipoprotein E. III.
Effect of single polymorphic gene locus
on plasma lipid levels in man. Clin.
Genet. 15: 63-72, 1979.

14.

Davignon J., Gregg RE., Sing CF.
Apolipoprotein E polymorphism and
atherosclerosis. Arteriosclerosis. 8: 121, 1988.

15.

Utermann G., Hordewing A., Zimmer F.
Apo E phenotypes in patients with
myocardial infarction. Hum. Genet. 65:
237-41, 1984.

16.

Lenzen HJ., Assman G., Bushwolsky R.,
Schulte H. Association of apolipoprotein
E polymorphism, LDL-C and coronary
artery disease. Clin Chem 32: 778-81,
1986.

17.

18.

Mahley RW., Palao¤lu KE., Atak Z.,
Pepin JD., Langlois AM., Cheung V.,
Onat H., Fulks P., Mahley L., Vakar F.,
Özbayrakç› S., Gökdemir O., Winkler W.
Turkish Heart Study: lipids, and
apolipoproteins. J Lipid Res. 36: 839859, 1995.
Eichner J.E., Kuller LH., Orchard TJ.,
Grandits GA., McCallum LM., Ferrell
RE., Neaton JD. Relation of
Apolipoprotein E Phenotype to
Myocardial Infarction and Mortality from
Coronary Artery Disease. AJC. 15: 160165, 1993.

19.

Cumming AM., Robertson FW.
Polymorphism at the apolipoprotein-E
locus in relation to risk of coronary
disease. Clin Genet. 25: 310-313
1984.

20.

Kuusi T., Nieminen NS., Ehnholm C.,
Yki-Ja(ö)rvinen H., Valle M., Nikkila(ö)
EA., Taskinen MR. Apoprotein E
polymorphism and coronary artery
disease. Increased prevalence of
apolipoprotein E-4 in angiographically
verified
coronary
patients.
Arteriosclerosis. 9: 237-241, 1989.

21.

Gregg RE., Zech LA., Schaefer EJ. Type
III hyperlipoproteinemia: defective
metabolism
of
an
abnormal
apolipoprotein E. Science. 211: 584-5,
1981.

22.

Bosu SK., HO YK., Brown M.., Bilheimer
DW. Biochemical and genetic studies on
the apolipoprotein E secreted by mouse
macrophages and human monocytes J.
Biol Chem. 257: 9788-95, 1982.

23.

Kesaniemi YA., Ehnholm C., Miettinen
TA. Intestinal cholesterol absorption
efficiency in man is related to
apolipoprotein E phenotype. J. Clin
Invest. 80: 578-81, 1987.

24.

Lin H., Ignatesau M., Wilson JE.,
Roberts CR. Prominence of apo B and E
in the intimae of coronary arteries in
transplanted human hearts: geographic
relationship
to
vessel
wall
proteoglycans. J. of Heart and Lung
Transplantation. 15 (12): 1223-32,
1996.

233

